Biomarker discovery: Validation and decision-making in product development

Sexually Transmitted Diseases

Volumn 36, Issue 3 SUPPL., 2009, Pages

  Niedbala, R Sam ^a   Mauck, Christine ^b,d   Harrison, Polly ^a,c   Doncel, Gustavo F ^b  

^a LEHIGH UNIVERSITY   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^c Alliance for Microbicide Development   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; ERLOTINIB; IMATINIB; MICROBICIDE; MOLECULAR MARKER; SUNITINIB; CA 125 ANTIGEN; CYCLOPHOSPHAMIDE; DNA; FLUOROURACIL; MESSENGER RNA; PACLITAXEL; PEPTIDE; PROSTATE SPECIFIC ANTIGEN; PROTEIN; TUMOR MARKER;

BIOINFORMATICS; CLASSIFICATION; CLINICAL ASSESSMENT; DECISION MAKING; DISEASE MARKER; DISEASE PREDISPOSITION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; EVALUATION; FOOD AND DRUG ADMINISTRATION; GENOMICS; HAIR LOSS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEASUREMENT; METABOLOMICS; NEUTROPENIA; PROTEIN ANALYSIS; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; RISK FACTOR; TRANSCRIPTOMICS; VAGINA CONTRACEPTION; VALIDATION STUDY; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DISEASE SEVERITY; EPIGENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; METABOLITE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOGENOMICS; POSITRON EMISSION TOMOGRAPHY; PRODUCT DEVELOPMENT; PROTEIN EXPRESSION; SEXUALLY TRANSMITTED DISEASE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION PROCESS;

BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; DECISION MAKING; DRUG DISCOVERY; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; PROTEOMICS;

EID: 62849111680     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e31819cd800     Document Type: Review

References (13)

1. US Department of Health and Human Services, Food and Drug Administration. Innovation or Stagnation: Challenge and opportunity on the critical path to new medical products. Available at: http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.html. Accessed March, 2004.
2. Adams CP, Brantner VV. Estimating the cost of new drug development: Is it really $802 million? Health Aff (Millwood) 2006; 25:420-428.
3. Laterza OF, Hendrickson RC, Wagner JA. Molecular biomarkers. Drug Inf J 2007; 41:573-585.
4. Bloom JC. Biomarkers in clinical drug development: Definitions and disciplines. In: Bloom JC, Dean RA, eds. Biomarkers in Clinical Drug Development. New York, NY: Marcel Dekker Inc, 2003:1-10.
5. Gerszten RE, Accurso FJ, Bernard GR, et al. Challenges in translating plasma proteomics from bench to bedside: Update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol 2008; 295:L16-L22.
6. 2. E-J Br Pharmacol Soc 4. 2006; 4. Available at: http://www.pa2online.org/articles/article.jsp7volume=5&issue= 13&article=54.
7. McGee P. Genomics 2007: The Next Step in the Sequence. Genomics and Proteomics Magazine. December, 2006:G4-G8.
8. Mummaneni P, Amur S, Goodsaid F, et al. Genomic biomarkers in FDA-approved drug labels. Poster D-04 presented at the 2006 FDA Science Forum. A Century of FDA Science: Pioneering the Future of Public Health; April 18-20, 2006; Washington, DC.
9. Norton PA, Comunale MA, Krakover J, et al. N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem 2008; 104:136-149.
10. Bren L. Metabolomics: Working toward personalized medicine. FDA Consumer magazine, November-December 2005 Issue. US Food and Drug Administration. Available at: www.fda.gov/fdac/ features/2005/605_metabolomics.html. Accessed October 24, 2008.
11. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001 [Erratum in: CA Cancer J Clin 2001; 51:144]. CA Cancer J Clin 2001; 51:15-36.
12. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003; 3:243-252.
13. Alliance for microbicide development. Mapping the microbicide effort. A companion to the Microbicide Development Strategy. Silver Spring, MD: 2007. Available at: http://www.microbicide.org.